Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2009.01.033 Byline: Elizabeth Barrett-Connor (a), David A. Cox (b), Jingli Song (b), Bruce Mitlak (b), Lori Mosca (c), Deborah Grady (d) Keywords: Framingham; Raloxifene; SERM; Stroke Abstract: Raloxifene reduces vertebral fracture and invasive breast cancer risks, but increases fatal strokes in postmenopausal women at increased coronary risk. We assessed whether this risk is concentrated in postmenopausal women already at high stroke risk. Author Affiliation: (a) Departments of Family and Preventive Medicine, University of California, San Diego, La Jolla, Calif (b) Lilly Research Laboratories, Indianapolis, Ind (c) Preventive Cardiology, Columbia University Medical Center, New York, NY (d) University of California, San Francisco and the San Francisco VA Medical Center, Calif Article Note: (footnote) Funding: Studies funded by Lilly Research Laboratories., Conflict of Interest: Elizabeth Barrett-Connor and Deborah Grady were paid external investigators for the Raloxifene MORE and RUTH studies by Lilly Research Laboratories. Lori Mosca was a paid external investigator for the Raloxifene RUTH study by Lilly Research Laboratories. David A. Cox, Jingli Song, and Bruce Mitlak are employees of Lilly Research Laboratories and have financial interest in the company., Authorship: All authors had access to the data and a role in writing the manuscript.